Frutarom to acquire specialty nutrition company Enzymotec for $210m

Israeli flavours and speciality fine ingredients maker Frutarom has agreed to acquire speciality nutrition company Enzymotec in a $210m deal.

The acquisition would strengthen Frutarom’s growing activity in natural speciality fine ingredients.

The deal includes integration of research and development, sales, marketing, production, supply chain and logistics activities of Enzymotec and Frutarom.

Frutarom will acquire a 100% stake in Enzymotec after receiving approval from the shareholders.

Frutarom president and CEO Ori Yehudai said: “This acquisition will provide additional reinforcement to our growing activity in natural specialty fine ingredients based on innovation, which is expanding at a rapid pace.

“This amicable transaction offers significant advantages to both parties, including a further boost in value for our shareholders along with providing a quick and efficient implementation of a growth strategy and profitability for Enzymotec’s operations.”

Enzymotec is involved in the production of nutritional ingredients and medical foods. It developed a technology to processing lipids that are an important nutritional element, therefore supporting various biological functions.

It has two segments named the nutrition and VAYA Pharma segments.

The nutrition segment of Enzymotec will contribute to the expansion of the portfolio of solutions for customers of both companies in the fields of pharmaceuticals, dietary supplements, designated foods for infants in the field of infant formula, and elderly clinical nutrition, Frutarom stated.